AzTrials
AzTrials

Liver DiseasesNCT05770284

Effect of Exercise Based Regimen on Frailty in Children With Liver Disease

A study testing 12 weeks exercise and Standard Medical Treatment in people with Liver Diseases, run by Institute of Liver and Biliary Sciences, India at 1 site in India.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Frailty is now a well-known complication of liver disease and various studies, including pediatric literature studies, have recognized it as a poor prognostic factor in CLD as well as liver transplant settings. It is associated with poor quality of life, increased hospitalisation and mortality. Read more about this study

Who is it for?
Ages 9 to 18 years
Conditions the study is for
Liver Diseases
What is being tested?
12 weeks exercise and Standard Medical Treatment
Could I receive a placebo?
No, everyone receives an active treatment
How many people
46 participants
Where
1 siteIndia
Study dates
15 Mar 2023to 2 Nov 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 9 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Children 9 - 18 years age with chronic liver disease \& frailty score > 5.

Who cannot join

  • Lansky play performance scale <50
  • Unable to do exercise under supervision on at least 2 occasions
  • Children on higher corticosteroid dose (>0.1mg/kg/day) in last 12 weeks
  • Any degree of musculoskeletal involvement (myopathy/limb deformity/paraplegia)
  • Children with any cardiac disease
  • Children with neurological Wilson
Show all 13Show fewer
  • Uncontrolled portal hypertension (persistent high-risk varices) Recurrent variceal bleed ≥ 2
  • Any degree of hemodynamic instability
  • Current hepatic encephalopathy (any grade)
  • Grade 3 ascites
  • Hepatic hydrothorax
  • Any degree of oxygen dependence
  • Severe or Very severe Hepatopulmonary syndrome (room air PaO2 < 60 mm Hg).

Trial locations and contacts

1 site in 1 country.

India1 site
  • Institute of Liver & Biliary Sciences

    New Delhi, National Capital Territory of Delhi, 110070

Other trials in India

About this study

Official title: Effect of Exercise Based Regimen on Frailty in Children With Liver Disease -A Randomized Controlled Trial

Frailty is now a well-known complication of liver disease and various studies, including pediatric literature studies, have recognized it as a poor prognostic factor in CLD as well as liver transplant settings. It is associated with poor quality of life, increased hospitalisation and mortality. Exercise for >12 weeks leads to improvements in aerobic power (peak VO2), aerobic endurance, muscle mass and strength, health related quality of life (HRQoL)(1). Although effect of Exercise on sarcopenia and frailty has been studied extensively in cirrhotic adults, there is paucity of such literature on the effect of exercise on frailty in children. Through this study, we aim to assess efficacy of exercise-based regimen on frailty in children with chronic liver disease after 12 weeks. Our secondary objective will be to compare outcome between the two groups(frail and non frail children with liver disease) and to compare change in frailty scores between the two groups. Other objectives will include assessment of the body composition analysis and the myokines and hepatokines signatures of children with liver disease (pre and post exercise intervention).

Read the detailed description

Methodology Study population: Children with liver disease fulfilling the conditions as per inclusion and exclusion criteria

Baseline parameters that will be recorded:

  • Clinical parameters:
  • History and etiology of liver disease
  • Symptomatology, Evidence of decompensation (jaundice, organomegaly, encephalopathy, ascites, infections, variceal bleed etc)
  • PELD, MELD Na score, Lansky play performance score
  • Baseline laboratory parameters: Complete blood count, LFT, KFT, PT-INR, ammonia etc
  • Imaging parameters: liver and spleen size, portal vein size etc
  • Anthropometric parameters:
  • Weight for age
  • Height for age
  • BMI
  • Triceps skin fold thickness
  • Subscapular fold thickness
  • Mid arm circumference

Calculation of frailty score:

Cut-off for frailty will be defined as frailty score >5 in children with liver disease.

Methodology for Frailty assessment:

Assessment of the 5 Fried Frailty Criteria would be performed at baseline in an ambulatory setting .The Fried Frailty assessment would be done in children with liver disease. The assessments will be typically performed by a combination of a doctor, dietician and physiotherapist.

Weakness-Grip strength would be measured using a handheld device, the Jamar Hand Dynamometer. The device would be squeezed 3 times by each hand, and the mean value of the recorded strength (in pounds) was taken as the final result and compared with standard values for age and sex. Slownessor endurance would be assessed by the 6-minute walk test (6-MWT). Children will use a standard hand wheel to capture the walked distance on a hard flat surface at their own pace. The covered distance expressed in meters (m) will be compared with standard values for sex and age. Shrinkage in children would be assessed by triceps skin fold thickness (TSF) measurements. TSF would be measured in triplicates by a dietician and the mean result was recorded in centimeters (cm) and compared with the Center for Disease Control age and sex normative values. Exhaustion-the Pediatric Quality of Life Inventory 4.0 Multidimensional Fatigue Scale, a validated pediatric questionnaire, would be used to assess fatigue. Diminished Physical activity-For children the age appropriate versions of the validated Modified Physical Activity Questionnaire (PAQ) (PAQ-A for children >13 years of age and PAQ-C for children< 13 yearof age will be used .

Along with routine investigations including Complete Blood counts, Liver function and Renal function test, PT-INR, serum Ammonia, the following investigations will also be done:

  • Myokines (myostatin, decorin, irisin) and hepatokines (follistatin) levels in blood and urine at baseline and after 12 weeks of exercise therapy in study 2.
  • Body composition analysis: Following parameters would be assessed: skeletal Muscle Mass; Body fat Mass; whole Body phase angle; segmental lean Analysis at baseline and after 12 weeks of exercise therapy in study 2.

Following enrolment and those fulfilling inclusion criteria, patient will then be allocated into exercise with SMT or SMT alone group as per block randomization method. Exercise with SMT or SMT alone will be given for a period of 12 weeks. Patient will be followed up for a period of 12 weeks. At the end of 12 weeks, frailty score will be recalculated .Body composition analysis,myokines and hepatokines will be repeated after 12 weeks.

Occurrence of clinical events including new onset ascites, AKI, hepatic encephalopathy, upper GI bleed and overall hospital stay as well as mortality over 12 weeks and 6 months will be noted in both groups during this period and treated as per standard of care. These events will be defined as follows-

  1. Acute Kidney Injury As per KDIGO guidelines:
  • Increase in serum creatinine by more than 0.3mg/dl within 48 hours, OR
  • Urine output less than 0.5ml/kg/hour for more than 6 hours, OR
  • Increase in serum creatinine by more than 1.5 times the baseline presumed/known to have occurred within prior 7 days.
  1. Hepatic encephalopathy: as per Modified West-Haven's criteria.
  2. Grades of ascites Grade 1- ascites only detected by ultrasound Grade 2 -moderate ascites evident by distension of abdomen with shifting dullness Grade 3- gross/tense ascites with marked abdominal distension Study period: 2 years

Intervention (Study 2):

  • Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc
  • Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol)
  • Aerobic exercises consist of Brisk walking
  • Resistance Exercises consist of movements targeting the major muscle groups with weight lifting
  • Intensity:

Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10.

  • Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength End point: 12 weeks

Stopping rule:

  • Interruption of Exercise for > 7 consecutive days due to non-compliance or clinical events.
  • Progression to exclusion criteria i.e. decompensation etc Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day, and this will be ensured in regular follow-up as a standard care of practice developed by the department of Pediatric Hepatology.

Monitoring and assessment:

Patients will be followed up for a period of at least 3 months. Occurrence of clinical events including new onset ascites, AKI, hepatic encephalopathy, upper GI bleed, significant infections will be noted in both groups during this period and treated as per standard of care.

At the end of 12 weeks, frailty assessment will be repeated along with myokines and hepatokines, body composition analysis and anthropometric examination.

Adverse effects:

There are no expected adverse effects of exercise as seen in previous studies.

Stopping rule of study:

  • Interruption of exercise for more than 7 consecutive days due to non-compliance or clinical events.
  • Progression to exclusion criteria i.e decompensation
  • Potential liver transplant within 1 month.
Conditions
Liver Diseases
Being tested
12 weeks exercise, Standard Medical Treatment
Medical subject headings
Liver Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 12 weeks exerciseOther

    12 weeks exercise

  • Standard Medical TreatmentOther

    Standard Medical Treatment

Study groups in NCT05770284
Study groupRoleWhat they receive
Subject will receive 12 weeks of exercise with standard medical management (SMT)Experimental* Subjects will be given exercise protocol Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc * Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol) * Aerobic exercises consist of Brisk walking * Resistance Exercises consist of movements targeting the major muscle groups with weight lifting * Intensity: Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10. * Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength * End point: 12 weeks * Stopping rule: * Interruption of Exercise for > 7 consecutive days due to non-compliance or clinical events. * Progression to exclusion criteria i.e. decompensation etc Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day
Receives: Other: 12 weeks exercise; Other: Standard Medical Treatment
standard medical management (SMT)Active comparatorstandard medical management (SMT)
Receives: Other: Standard Medical Treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence of Frailty in children with liver disease.

    Fraility assessment criteria will be based on 5 elements:

    1. weakness will be assessed by grip strength.
    2. slowness will be by 6 minutes walk test.
    3. shrinkage by triceps fold thickness.
    4. exhaustion by validated pediatric PedsQL 4.0 multidiamential fatigue scale.
    5. diminshed physical activity by modified PAQ

    Measured: 0 day

  2. Improvement in Frailty after 12 weeks of exercise therapy in children with CLD and Frailty.

    Improvement will be based on five fried fraility criteria with fraility score> 5

    Measured: 12 weeks

Secondary outcomes (9)
  1. Increase in skeletal muscle mass in Body composition analysis after 12 weeks of exercise regimen

    Measured: 12 weeks

  2. Decrease in the occurrence of Hepatic Encephalopathy based on modified West Haven criteria in the exercise regimen with SMT group versus SMT alone.

    Measured: 3 months

  3. Decrease in the occurrence of Upper Gastrointestinal bleed (presence or absence of GI bleed) in the exercise regimen with SMT group versus SMT alone.

    Measured: 3 months

  4. Decrease in the occurrence of significant events including Spontaneous Bacterial Peritonitis in the exercise regimen with SMT group versus SMT alone .

    Measured: 3 months

  5. Decrease in the occurrence of significant events including Acute Kidney Injury in the exercise regimen with SMT group versus SMT alone .

    Measured: 3 months

  6. Decrease in the occurrence of significant events including new onset or increase in ascites in the exercise regimen with SMT group versus SMT alone .

    Measured: 3 months

  7. Decrease in the occurrence of significant events including hospital stay in the exercise regimen with SMT group versus SMT alone .

    Measured: 3 months

  8. Decrease in the occurrence of significant events including mortality in the exercise regimen with SMT group versus SMT alone .

    Measured: 3 months

  9. Decrease in myostatin levels after 12 weeks of exercise regimen

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Mar 2023
  2. Study start15 Mar 2023
  3. Primary completion2 Nov 2024
  4. Study completion2 Nov 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
46 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05770284
Sponsor's protocol ID
ILBS-Liver Disease-02
Status last verified
Jan 2025
First submitted
8 Feb 2023
Last updated
8 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing 12 weeks exercise and Standard Medical Treatment in people with Liver Diseases, run by Institute of Liver and Biliary Sciences, India at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevalence of Frailty in children with liver disease. (time frame: 0 day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in